Eli Lilly announced on July 20 its plan to acquire AtaiBeckley for up to $3.8 billion, marking what analysts say is the largest endorsement of the psychedelics sector by a major pharmaceutical company to date.
H.C. Wainwright analysts said in a note that "Lilly’s pending acquisition of AtaiBeckley is the clearest strategic validation to date of psychedelics and interventional psychiatry as an emerging pharmaceutical category." The analysts also said that with this buyout, "Lilly raises the floor, and the bar" for the space and shifts large-cap biopharma participation from partnerships or selective asset acquisitions to full ownership of a public platform focused on a Phase 3 short-duration psychedelic.
The deal follows AbbVie’s $1.2 billion acquisition of Gilgamesh Pharmaceuticals’ bretisilocin in October 2025. H.C. Wainwright cautioned that not all psychedelics biotechs are equal, stating that Lilly's move "should not be interpreted as supporting a uniform re-rating of every psychedelic developer: it raises the strategic floor for differentiated late-stage assets while also raising the bar for clinical maturity, indication selection, intellectual property, treatment duration, durability, and real-world scalability."
AtaiBeckley’s lead compound BPL-003 is a synthetic form of 5-MeO-DMT being studied as a nasal spray treatment for treatment-resistant depression (TRD) and is currently in Phase 2 development. In a Phase 2a trial, BPL-003 produced an antidepressant response in 66.7% of patients by day two. Jefferies described it as “a differentiated short-duration psychedelic that has shown rapid, meaningful, and durable efficacy” in TRD.
Analysts noted both AbbVie’s bretisilocin and Lilly's target asset fit into the trend toward shorter-duration therapies with clinic-friendly administration windows: “Both AbbVie and Lilly paid up for shorter-duration assets... reflecting the strategic value of clinic throughput and a lower episode-of-care burden.” However, H.C. Wainwright said that commercial success depends on maintaining compelling clinical effects while reducing costs and operational burdens.
While earlier focus in contemporary psychedelics was post-traumatic stress disorder (PTSD), depression—especially TRD—has become central after Lykos Therapeutics' MDMA-assisted PTSD therapy failed approval in August 2024. Compass Pathways’ COMP360 targets TRD as well; recent trial results showed clinically meaningful reductions in depression severity among recipients by week six after dosing.
